JS Link

JS Link EBIT Growth

The Year-over-Year EBIT Growth of JS Link (127120.KQ) as of Oct 26, 2026 is -181.17 %. In the previous year, Year-over-Year EBIT Growth was 39.71 % — a change of -556.25% (lower).

EBIT Growth

-181.17 %

YoY

-556.25%

Last updated:

Year-over-Year EBIT Growth of JS Link is 2024 -181.17 % . Year-over-Year EBIT Growth of JS Link was 2023 39.71 % . It decreases by -556.25% lower compared to the previous year.

The JS Link EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2017
111.18 KRW
Jan 1, 2018
-563.57 KRW
Jan 1, 2019
-98.44 KRW
Jan 1, 2020
-20.92 KRW
Jan 1, 2021
42.51 KRW
Jan 1, 2022
-46.28 KRW
Jan 1, 2023
39.71 KRW
Jan 1, 2024
-181.17 KRW
The JS Link EBIT Growth history
YEAREBIT GrowthYoY
-181.17 %-556.25%
39.71 %-185.79%
-46.28 %-208.88%
42.51 %-303.21%
-20.92 %-78.75%
-98.44 %-82.53%
-563.57 %-606.91%
111.18 %-9,286.40%
-1.21 %-98.76%
-97.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JS Link Stock analysis

What does JS Link do? DNA Link, Inc. generates revenue through its genomic analysis services and products. The company offers genome biomarkers excavation products via the enhanced genome integration system (EGIS) brand, which includes high-quality data products, genomic analysis interpretation, and molecular diagnostic kit production technologies. Additionally, DNA Link provides personal genome analysis services under the deoxyribonucleic acid personalized services (DNAGPS) brand, targeting individuals seeking personalized genetic insights. The primary customers for EGIS are healthcare providers and research institutions requiring integrated genomic and clinical data solutions, while DNAGPS serves individual consumers interested in personalized health information. The enhanced genome integration system (EGIS) brand focuses on delivering comprehensive genomic analysis and clinical information integration, catering to the needs of medical professionals and research organizations. DNAGPS targets individual users who want detailed personal genome reports. Both product lines leverage DNA Link's expertise in genomic analysis and molecular diagnostics, ensuring high-quality data and interpretation services. The company's revenue streams are driven by the sale of these branded products to their respective target segments. DNA Link's business model centers around two core product lines: EGIS for professional and institutional clients and DNAGPS for individual consumers. EGIS products are sold to healthcare providers and research institutions that require advanced genomic data analysis and molecular diagnostic solutions. DNAGPS services are marketed directly to consumers seeking personalized genetic information. The company's revenue is derived from the licensing and sale of these branded genomic analysis services and products, with no mention of additional revenue sources in the business description. JS Link is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JS Link stock

Year-over-Year EBIT Growth of JS Link is -181.17 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth JS Link since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's JS Link historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — JS Link

All Key Metrics — JS Link